KOD - Kodiak Sciences Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
60.71
-0.65 (-1.06%)
As of 9:46AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close67.89
Open61.00
Bid60.05 x 900
Ask61.03 x 1200
Day's Range60.05 - 61.79
52 Week Range5.65 - 74.50
Volume31,598
Avg. Volume616,856
Market Cap2.3B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.25
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.17
  • PR Newswire

    Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes 900,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $46.00 per share. The aggregate gross proceeds from the offering were approximately $317.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences.

  • PR Newswire

    Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock

    Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $46.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $276.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. The offering is expected to close on or about December 6, 2019, subject to customary closing conditions. In connection with the offering, Kodiak Sciences has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

  • Benzinga

    Benzinga Pro's Top 6 Stocks To Watch For Tues., Dec. 3, 2019: CARA, VRAY, LE, KOD, FXI, ROKU

    Benzinga Pro's Stocks To Watch For Tuesday Cara Therapeutics (CARA)  - The company announced the Phase 2 trial of oral KORSUVA achieved the primary endpoint but did not achieve statistical significance ...

  • Benzinga

    The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 2.) Aquestive Therapeutics Inc (NASDAQ: AQST ) ...

  • PR Newswire

    Kodiak Sciences Announces Proposed Offering of Common Stock

    Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $250,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be sold by Kodiak Sciences. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

  • Longtime biotech investor injects $250M into Palo Alto company a year after IPO
    American City Business Journals

    Longtime biotech investor injects $250M into Palo Alto company a year after IPO

    Eye drug developer Kodiak Sciences Inc. lined up a royalty rights deal with longtime biotech investor Baker Bros. Advisors LP for $225 million and the promise of another $25 million in the Palo Alto company's next stock raise.

  • PR Newswire

    Kodiak Sciences to Present at the Evercore ISI HealthCONx Conference

    Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Evercore ISI HealthCONx Conference in Boston, MA on Tuesday, December 3 at 1:15 p.m. Eastern Time.

  • PR Newswire

    Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors

    Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million. KSI-301 is Kodiak's investigational therapy being developed for the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases.

  • 5 Stocks That Pushed Russell 2000 ETF Higher
    Zacks

    5 Stocks That Pushed Russell 2000 ETF Higher

    Inside the best performing stocks of the Russell 2000 ETF.

  • Benzinga

    The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...

  • PR Newswire

    Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights

    PALO ALTO, Calif. , Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019

    PALO ALTO, Calif. , Nov. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from its ongoing Phase 1b study of its investigational therapy KSI-301 in patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). The results were presented by Charles C. Wykoff, M.D, Ph.D., a clinical investigator in the study, as an oral presentation at the "First-Time Results of Clinical Trials" session of the American Academy of Ophthalmology Annual Meeting's Retina Subspecialty Day.

  • PR Newswire

    Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

    PALO ALTO, Calif. , Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate ...

  • PR Newswire

    Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

    PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak's anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with treatment-naïve wet (neovascular) age-related macular degeneration (AMD). "Treating the first patients in this pivotal study is an important step for Kodiak as we grow the company and accelerate our efforts with KSI-301," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "On World Sight Day, we recognize that patients with wet AMD often need frequent eye injections of an anti-VEGF medication to preserve their vision.

  • PR Newswire

    Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

    PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff, M.D., Ph.D., will present first-time results at the Annual Meeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco, California. The Retina Subspecialty Day (October 11 – 12) will feature a presentation of emerging data from the Phase 1b clinical study of KSI-301 in treatment-naïve patients with neovascular age-related macular degeneration (wet AMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).

  • Disappointed by WeWork? Check Out These IPO Stocks.
    InvestorPlace

    Disappointed by WeWork? Check Out These IPO Stocks.

    For loyal followers of Matt McCall's "Moneyline" podcast, you'll notice a callback in this week's episode. Early in September, he warned investors to stay away from the WeWork IPO, and boy, was he right. In the last few weeks, the company delayed and then cancelled its IPO. Why? Allegations of co-founder Adam Neumann's drug use and company management took over headlines. Just this morning, WeWork announced it would cut as much as 25% of its workforce.So then how do you invest safely in IPO stocks? McCall urges investors to do "boots-on-the-ground" research to get a better feel for a company. He also warns listeners not to get distracted by a CEO's charisma or long, flowing hair. Using that research, he put together a list of compelling IPO stocks from 2019.While Beyond Meat (NASDAQ:BYND) stock has performed well this year, it doesn't make the list. Instead look to lesser-known names. Kodiak Sciences (NASDAQ:KOD), Palomar Holdings (NASDAQ:PLMR) and Yeti (NYSE:YETI) are some of his top picks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? What's different about these picks? They're "real" companies that will make shareholders money. On the flip side, WeWork might have been a great stock to talk about at bars, but it's a losing play. McCall's PodcastIPO stocks aren't the only thing McCall has advice on. In this week's episode of "Moneyline," he's back to his soothing words on the state of the stock market today. As rumors of a global recession and an ending bull market soar, he maintains that we've got at least one rally left.How does he determine this? Well, he looks at all that's bad and good in the investing world right now. The U.S.-China trade war, talks of President Donald Trump's impeachment and an ongoing UAW strike against General Motors (NYSE:GM) are weighing the market down. But a supportive Federal Reserve and low rates of unemployment are big positives. Plus, as McCall says, if the White House can be slightly less manic, there's huge upside ahead.Oh, and you've probably heard the news that Interactive Brokers (IEX:IBKR) led the trend of online brokers offering commission-free trading. In recent days, Charles Schwab (NYSE:SCHW), E*Trade (NASDAQ:ETFC) and TD Ameritrade (NASDAQ:AMTD) have joined its ranks. Is this a sure sign that online brokers are doomed? No. Listen in for more information on what this means, how Robinhood is involved and how you can turn this news into a great retirement savings opportunity.Tune in to Matt McCall's "Moneyline" podcast to learn more about all this, and above all else, remember not to panic next time you turn on the news.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best ETFs for 2019: The Race Is a Little More Gnarly Now * 7 Next-Generation Healthcare Stocks to Buy * Are These 10 High-Yielding S&P Dividend Stocks Traps or Treasures? The post Disappointed by WeWork? Check Out These IPO Stocks. appeared first on InvestorPlace.

  • PR Newswire

    Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

    Late-breaking results support Kodiak's objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD KSI-301 continues towards its development goals of demonstrating ...

  • PR Newswire

    Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London, U.K. "Developing intravitreal medicines with meaningfully differentiated durability has been Kodiak's objective since our founding one decade ago. Kodiak's announcement at this weekend's Retina Society Annual Meeting takes us another step closer to providing a transformative new therapeutic option to patients.  I believe KSI-301 has the potential to be a first-line anti-VEGF agent for patients suffering from retinal vascular diseases," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.

  • PR Newswire

    Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference

    PALO ALTO, Calif. , Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

    PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at EURETINA 2019 Congress being held from September 5 – 8 in Paris, France. "We continue to be pleased with the promising efficacy and safety data of KSI-301," said Victor Perlroth, M.D., Kodiak's Chief Executive Officer. "At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301.

  • Kodiak Sciences Inc. (NASDAQ:KOD) Insiders Increased Their Holdings
    Simply Wall St.

    Kodiak Sciences Inc. (NASDAQ:KOD) Insiders Increased Their Holdings

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • PR Newswire

    Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights

    PALO ALTO, Calif. , Aug. 14, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • PR Newswire

    Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference

    PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal ...

  • Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting
    PR Newswire

    Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting

    - Antibody Biopolymer Conjugates are a new scientific approach and design platform for ophthalmic intravitreal drugs - KSI-301 continues to achieve its development goals of demonstrating efficacy and safety ...